Home Newsfeeds Morgan Stanley Reinstates Equal-Weight on Virgin Galactic Hldgs, Announces $4 Price Target

Morgan Stanley Reinstates Equal-Weight on Virgin Galactic Hldgs, Announces $4 Price Target

Morgan Stanley analyst Kristine Liwag reinstates Virgin Galactic Hldgs (NYSE:SPCE) with a Equal-Weight and announces $4 price target.

byBenzinga Newsdesk

January 10, 2023

1 minute read

Morgan Stanley analyst Kristine Liwag reinstates Virgin Galactic Hldgs (NYSE:SPCE) with a Equal-Weight and announces $4 price target.

Analyst Ratings

Peeling Back The Layers: Exploring Vestis Through Analyst Insights

By Benzinga Insights

May 3, 4:01 PM

5 analysts have expressed a variety of opinions on Vestis (NYSE:VSTS) over the past quarter, offering a diverse…

VSTS

What’s Going On With Canopy Growth Stock Tuesday?

By Erica Kollmann

July 11, 11:05 AM

Canopy Growth Corporation (NASDAQ: CGC) shares are moving higher on heavy trading volume Tuesday. What To Know:

CGC

Southwest Airlines Recovery Pushed to 2025: Profitability Delayed, but Strong Balance Sheet Remains Intact, Analyst Says

By Anusuya Lahiri

July 28, 1:43 PM

Raymond James analyst Savanthi Syth downgraded the Southwest Airlines Co (NYSE: LUV) stock from Strong Buy to Outperform and cut the price target on Southwest Airlines

LUV

Galecto’s Myelofibrosis Candidate Reduces Bone Marrow Fibrosis

By Vandana Singh

September 29, 11:17 AM

Galecto Inc (NASDAQ:GLTO) announced results from a planned intermediate assessment of its ongoing MYLOX-1 Phase 2a trial of GB2064 for myelofibrosis.…

GLTO

Morgan Stanley Reinstates Equal-Weight on Virgin Galactic Hldgs, Announces $4 Price Target

Related Posts

Peeling Back The Layers: Exploring Vestis Through Analyst Insights

What’s Going On With Canopy Growth Stock Tuesday?

Southwest Airlines Recovery Pushed to 2025: Profitability Delayed, but Strong Balance Sheet Remains Intact, Analyst Says

Galecto’s Myelofibrosis Candidate Reduces Bone Marrow Fibrosis